Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From Nov30 article "According to CEO Leo Ehrlich, that study will be un-blinded and top-line data will be released in about a week".
We are still clearly within the about a week time frame.
Sleeping better after this week. Solid run up on anticipation, good results which I expect and off to the races .
Amateur next week, assuming BOM results are released, is merely a stepping stone. Just watch.
GO IPIX - stay the course
BOM soon. Who cares when. All that matters is the data. Billion market. Sleep well all
Mrs Claus Same to you. I see from your many posts on various message boards that you really get around.
* * $IPIX Video Chart 12-08-17 * *
Link to Video - click here to watch the technical chart video
Brilacidin and prurisol trial design was set up to make the potential more clear.
I very much doubt the lines will he skewed, whoever the CDA's are with helped design them exactly for what they wanted to see.
Click the "easy" button.
And for kevetrin as well.
I think we'll be closing 2017 with quite a bang. And pushing through 2018 is going to be amazing. But that's my dd talking.
Time to get the weekend going.
Cheers!
Jim
A public service!
If the release is not hazy or ambiguous, SP will skyrocket on strong results. A poor release that hints at manipulation, look out below.
I figured today would be down more, that's why I held and then added near the bell.
I sure hope OM results are clear and are presented clearly, without ambiguity or hints of manipulation.
123tom
Maybe good news or an offer got in the way?
Echo20
So the next week is big expectation week - B-OM data - will it make it or break it?
On Dec 5th - 2 co in NASH space posted trial results
One went down by 46% and other went up by more than 100% - crossed mc of $1 B
What will B-OM do to IPIX SP? Significantly down or up?
Back inside the Bollingers is a good thing, flagging for another move. We could see even more accumulation starting Monday. I mentioned to Tom 2 days ago that the thing to watch was the momentum. I think the ones that kept this from going were the short termers.
We'll be leaving them in the dust. Munch all you can imo. We just might mot see under the $ again. And if we do, I doubt by much. I myself stopped waiting for a couple pennies when I want something.
And when this puppy does start moving again? I'll be saying I wish I had more.
Another deposit going in.
$IPIX
Have a great weekend!
Cox has a long history of BS so don't put faith in what he says. Company said "this Quarter" in late October.
did the same. will add more monday if under a buck early
Added 5,000 at $1.02. Common BOM data -- be good!
Aspire on the ask at $1.02??? quite a few shares available.
$1.08 was the targeted second resistance and it has proven to be firm. Strong OM results could blow it away.....
Amen to that!!!
Putting the investment in perspective.
Most seem to agree this is a buy and hold stock, waiting for a buyout or partnership. That said, the time to buy was at the bottom in the 60's and 70's.
Playing with shares here at 1 dollar ,looking for a dip to 90, is a gamble with trading shares at best. I hope investors bought their core in the 60's when they had many chances.
Rd88... at the moment I don't see a plunge as imminent, but it does seem waiting for news. Did they say news would be released this week?
If they did, then that could become worrisome now. Did they say Monday? or early next week? Patrick Cox said he expects it in about a week from his report (November 30)
It would be a chance to buy a decent plunge maybe. something like 90 cents or 88 area. (93-83) maybe. but I hope they aren't going to hit us with a lot of clever tricks.
Right now, ending the week, theyre making it appear that 1 dollar is holding ok.
5k bought on the ask. Someone reading this board closely.
News any minute.
See you all next year, I wish you all well and have a safe and happy holidays. Wish IPIX the best and success next year beyond all expectation.
There's no interest on the ask since late morning. Buyers went home early, with the usual suspects (Aruda/Aspire) nibbling away at the bid. Notice most of the trades today have been small blocks... This is how they sell to prevent a dramatic drop. One large buyer can move this back to 1.08 which seems to be the new ceiling.
Not saying Leo will do it but I hope he drops OM news at a time calculated to inflict the greatest pain possible on those who have tried and continue to try destroying the company he and Menon built.
After today's close could be Leo's 'Honey Badger' moment.
I agree. maybe Monday has a chance as well.
The market must be expecting good news, because the plunging sell offs have stopped. there was the initial plunge from 99 to 93, then from 1.17 to 1.03, and since then its been rather mild. and now so far 1 dollar has held. If news is really positive we could see a 1 dollar jump right to 2 dollars.I wouldn't be surprised.
that is true when shareprice escalates heading into a known conference. That is when share price usually falls back, after the conference. However, this time is Different! We know that results are SOON to be released. NO, not this week, but sometime between right now and end of the year, most probably in the next week and likely very GOOD news. Some will take profits ... we are not going straight up. IMO, those selling now are missiong out on much larger gains
Rdunn88
Could be a shakedown.
Good test results could occur Monday/Tuesday.
Echo20
Usually bad news is released on a Thursday or Friday after the close. I'm expecting Monday morning, Tuesday at the latest. This type of news generally isn't realsed during the day either.
Good sell at 1.17 Tom. Appears we're heading back under a buck. Not really a surprise if we look at the history. We got fooled believing OM data would be released this week. Nothing is ever early or on-time in IPIX world. But, Leo gave him a cushion with a Q4 deadline.
If it drops today as short term gains are taken, then it will likely drop a bit more Monday sans news.
That said, a drop in the next 40 minutes and I might nibble a bit.
Data could be released this afternoon. I've seen trial results come out on Fridays from other companies. Would be a big splash for the whole weekend.
Should be a "sticky"
Karin and Slci = Thank you for the additional info. Have a wonderful weekend all TRUE long. looking forward next week events.
That's also very possible.
Its been idle at 1 dollar waiting for the news these last few days.
no dips to buy, no surges to sell.
I'll be surprised if we don't get a late day rally. Results should come Monday before the open.
Setting up for a dollar close so predictable. We'll see if Leo can keep the rally going or become scrooge?
Endpoints: Yep – and folks arguing the contrary should note the increasing push for Surrogate Endpoints as “validation” of a drug’s efficacy, more wiggle room given to those under “accelerated approval”
If B-OM results pan-out in Primary—Yipee
But the Secondary/Exploratory measures should not be discounted, esp in a Ph2 (non-pivotal trial)
Summary [slide 19]
• For marketing approval, there must be substantial evidence (consisting of adequate and well-controlled investigations) of something that matters
• The primary endpoint(s) of confirmatory Phase 3 trials should represent (directly or through a validated surrogate) something that matters to a patient.
• There is a pathway for approval based on something that probably matters (an incompletely validated surrogate), but this comes with certain commitments. (“Subpart H” “accelerated approval”)
• Patient reported outcome (PRO) instruments and composite endpoints may be used to establish a benefit
https://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM337268.pdf
Multiple Endpoints in Clinical Trials (Draft Guidance)(2017)
“Because most diseases have more than one consequence, many trials are designed to examine the effect of a drug on more than one endpoint. In some cases, efficacy cannot be adequately established on the basis of a single endpoint. In other cases, an effect on any of several endpoints could be sufficient to support approval of a marketing application.”
https://www.federalregister.gov/documents/2017/01/13/2017-00695/multiple-endpoints-in-clinical-trials-draft-guidance-for-industry-availability
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf
Good post slcimmuno... Fully agree, but, I'll add that any large pharma looking to partner/license will also understand this even if most investors don't.
In Reply to 'slcimmuno'
for reals now - i simply linked to / cut-paste my response to a post of yours ---- primary imo will be met and moreover, shored up with secondary/exploratory endpoints
what you fail to understand is that most other OM drugs in trial are going after Duration / Onset not Incident as primary
so by def IPIX could fail its primary (Incidence) but still perform well as others in the secondary (Onset, Duration)
market might care (prob though because it might not understand as well as some of us IPIX trial design), but FDA sure wouldn't care which is Primary, which is Secondary --
it'll all come down the FULL dataset ... Incidence, Onset, Duration... plus all the other measures
case closed
noretreat, I wonder if you might get that better price today in the final hour.
I wouldn't be surprised to see a 10 cent dump very soon.
Held ok at 1 dollar so far today
All have been waiting so long for trial data events to unfold to IPIX while others who have been loyal visionaries for years remained vigilant and believing in Leo and company management till this day.
THE MOMENT OF TRUTH HAS ARRIVED! ....New ,Existing or Sideline investors what will it be ?....I predict stellar Brilacidin results and its stellar due diligence and science which in turn will lead to tough choices as an opportune investor here or a much higher pps possible and starting Monday morning ?....all imho,tryz
Not necessarily. A dosing amount and/or dosing frequency could be the issue or a subpopulation of patients where efficiency was actually met.
And changes could possibly rewrite to favorable outcome.
No one predicts exactly how a stock behaves. But it is not unexpected for IPIX to rise in anticipation of good news, and no surprise it is doing so. Clearly someone recently made a huge accumulation of shares, and others no doubt jumped in. This will not likely be the last time, nor will selling ever abate. As our commercial prospects firm up, the share price will generally tend upward over the long term. Good investors expect this, and only this. Looking forward to B results, and P and K in good time
EDIT: Going back through the releases on the Fidelity feed, I see several at 7am Eastern and a few recent ones when the market is open. Nothing really after the close except some form 4.
-----------
I will add under a buck where possible monday. I would not be surprised by the release when the market is open.
Leo used to do releases after the Friday close. Then the pattern shifted to before the open and not on Friday. Recently I believe there have been some release with the market open...not sure though. Anything is possible, including no release at all next week.
It is good to see the longs in a better mood around here...
After close Monday to premarket Tuesday. Edit as we go through the week, but NOT during market hours.
Yes, decent consolidation after more than a 40% gain is completely normal. I saw MAXM back on the LII, so they're expecting something soon too imo.
Talking about halts earlier, yeah, if we do get data during market hours Leo could halt the stock. I do believe.
We'll be truckin right through resistance soon imo.
$IPIX
#Leo puts $IPIX on the map
#EPIC year end results for Innovation Pharmaceuticals Inc. $IPIX
Controlled selling ongoing. What a monkey on IPIX back that Leo did with Aspire. They are, and have been kicking-butt out of the shareholder valuations.
Still waiting for Der Leo Wundewaffe that's just around the corner. For real this time ?
(Yep, I know...it's warming up the engines for the bast-off.)
The bunker is ready to explode from just tension.
Followers
|
975
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
403225
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |